NeoFipronis® (Pronidesivir) has been officially registered in Laos as a non-prescription veterinary medicine. The product contains GS-441524 and is formulated as oral tablets for feline infectious peritonitis (FIP)-related treatment management.
Vientiane, Laos — April 28, 2026 — Recently, some cat owners and partners have misunderstood NeoFipronis® (Pronidesivir) as a prescription-only medicine. To avoid confusion, NeoFipronis® provides the following clarification regarding the product’s regulatory status in Laos.
NeoFipronis® is the brand name of Pronidesivir, while GS-441524 is its active ingredient. The product has completed official registration in Laos and has been approved as a non-prescription veterinary medicine. It is available through authorized channels.
However, non-prescription veterinary status does not mean the product should be used casually or without proper consideration. Feline infectious peritonitis, commonly known as FIP, is a complex and serious feline disease. Diagnosis and treatment management should take into account clinical signs, body weight, laboratory results, imaging findings, and professional veterinary judgment.
Therefore, even though NeoFipronis® (Pronidesivir) has been approved in Laos as a non-prescription veterinary medicine, cat owners are still encouraged to consult a licensed veterinarian or qualified animal health professional before use.
NeoFipronis® (Pronidesivir) is formulated as oral tablets and is designed to provide a more convenient, traceable, and quality-controlled oral GS-441524 veterinary product option for FIP-related treatment management. Compared with products of unclear origin or unverified quality, products obtained through authorized channels help support authenticity, batch traceability, and quality consistency.
It is important to note that regulatory status, sales authorization, and permitted use of GS-441524-related products may vary by country or region. The non-prescription veterinary status of NeoFipronis® (Pronidesivir) in Laos does not mean that the product has the same regulatory status in every market. Cat owners, veterinarians, and partners should understand and comply with applicable local regulations before purchasing or using the product.
NeoFipronis® will continue to improve its product information system around “official registration, legitimate source, batch traceability, and quality control.” The website will provide product information, usage guidance, authorized-channel information, and verification support to help cat owners and veterinarians better understand NeoFipronis® (Pronidesivir).
NeoFipronis® (Pronidesivir) has been approved in Laos as a non-prescription veterinary medicine. However, FIP diagnosis, dosage planning, treatment duration, and monitoring should still be based on professional veterinary evaluation. Cat owners should not judge the condition based on a single symptom alone, nor should they adjust the dosage or discontinue treatment without professional advice.